INVIVYD INC. - COMMON STOCK

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

27 Aug 2024 07:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

14 Aug 2024 08:01:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

12 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

01 Jul 2024 07:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

14 Jun 2024 07:01:00 By Nasdaq GlobeNewswire

Invivyd to Participate at the Jefferies Global Healthcare Conference

03 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

31 May 2024 07:05:00 By Nasdaq GlobeNewswire

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

31 May 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd Elects Two New Independent Members to its Board of Directors

22 May 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 May 2024 16:01:00 By Nasdaq GlobeNewswire

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

09 May 2024 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

07 May 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

02 May 2024 17:13:02 By Nasdaq GlobeNewswire

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

30 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

15 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd Announces CEO Transition

12 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

04 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

28 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

22 Mar 2024 15:28:22 By Nasdaq GlobeNewswire